Virtual Screening and ADMET Prediction of RanBP9 Inhibitors for Alzheimer's Disease

As the most common type of dementia, Alzheimer's disease (AD) has affected over 44 million of people worldwide. To date, there is no disease-modifying medication that could help to reduce the key toxic peptide in AD pathogenesis, amyloid beta (Aβ), in brain. This study is aimed to identify pote...

Full description

Saved in:
Bibliographic Details
Published in2019 7th International Conference on Information and Communication Technology (ICoICT) pp. 1 - 5
Main Authors Tey, Han Jieh, Han Ng, Chong, Lim, Thong Leng
Format Conference Proceeding
LanguageEnglish
Published IEEE 01.07.2019
Subjects
ADMET prediction
Alzheimer's disease
Compounds
Diseases
Drugs
Inhibitors
Natural compounds
Proteins
RanBP9
Virtual screening
Online AccessGet full text

Cover

More Information
Summary:As the most common type of dementia, Alzheimer's disease (AD) has affected over 44 million of people worldwide. To date, there is no disease-modifying medication that could help to reduce the key toxic peptide in AD pathogenesis, amyloid beta (Aβ), in brain. This study is aimed to identify potential therapeutic agents that targeted on BACE1-interacting protein, RanBP9, from a natural compounds library. From the virtual drug screening and ADMET prediction result, compound 9 (ZINC8299685) and compound 15 (ZINC5415832) were identified as potential therapeutic agents in this study. Both compound 9 and 15 have low binding energy to the targeted protein, which are -8.3 and -7.6 kcal/mol, respectively. Besides that, both of the compounds possess desirable physiochemical and pharmacokinetics properties, including drug-likeness and bioavailability. The virtual screening and ADMET prediction results indicate that this two compounds are good drug candidates, which can be further validated in laboratory experiments.
DOI:10.1109/ICoICT.2019.8835252